Since there is evidence of mineralocorticoid receptor (MR) hyperactivation in patients with chronic kidney disease and diabetes, which could lead to an increased rate of inflammation first and fibrosis later, the blockade of receptor activity could contribute to the lowering of residual cardiorenal risk in such a patient population [2]. Here, NR3C2 is linked to diabetes mellitus.